Orthopediatrics Corp. · NASDAQ:KIDS
Orthopediatrics — Investor Presentation (October 2026)
33 slides from Orthopediatrics's investor presentation, Oct 27, 2026
Slide 1: 2026 Investor Presentation
2026 Investor Presentation www.OrthoPediatrics.com
Slide 2: Forward-Looking Statements
22 0 2 6 / / Forward-Looking Statements All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, oper
Slide 3: Over 1,425,000 pediatric patients treated since inception
32 0 2 6 / / pediatric patients treated since inception + 1,425,000 OrthoPediatrics was founded on the cause of impacting the lives of children with orthopedic conditions 1
Slide 4: Historical Challenges of Pediatric Orthopedics
01 Children’s unique clinical conditions Existing solutions are re-purposed from adult implants Limited development of new technologies No specialized sales force in Pediatric Orthopedics Limited industry support of clinical education 02 03 04 05 42 0 2 6 / / Historical Challenges of Pediatric Ortho
Slide 5: OrthoPediatrics Solution
52 0 2 6 / / OrthoPediatrics Solution 01 02 03 04 05 Product development focused exclusively on pediatric patients Broadest pediatric specific portfolio in the industry Delivering first in market novel surgical solutions Only global commercial channel to market Leading provider of surgeon clinical e
Slide 6: Only Focused Pediatric Orthopedic Company
62 0 2 6 / / Only Focused Pediatric Orthopedic Company Consistent YoY Growth Since Inception 1 Excluding COVID-impacted 2020 95+ unique pediatric systems Consistent cadence of innovative product launches Expanding suite of enabling technologies Internal R&D, acquisitions, and partnerships Only globa
Slide 7: Total Global Addressable Market – $6.2B
72 0 2 6 / / Total Global Addressable Market – $6.2B Competitive Dynamics $610M Trauma & Deformity Correction Implants $340M Scoliosis Fusion Impants $80M Scoliosis Non- Fusion Implants $60 EOS Implants $775M Specialty Bracing $250M Sports Medicine Implants $165M Growing Implants $500 Enabling Techn
Slide 8: Strategic Pillars
82 0 2 6 / / Strategic Pillars 02 Provide a broad product portfolio uniquely designed to treat children, surround pediatric orthopedic surgeons covering their needs 04 Expand addressable market through aggressive investment in R&D and select M&A opportunities 05 Train next generation of pediatric or
Slide 9: Focus on High-Volume Children's Hospitals
92 0 2 6 / / Comments ~1,700 Fellowship Trained Pediatric Surgeons Majority of Pediatric Centers are Teaching Hospitals Centers Treat Most Complex Pediatric Conditions ~80% of Pediatric Surgeons time is Non-Surgical 01 02 03 01 Focus on High-Vol Children’s Hospitals Current US Target Market – $1.6B
Slide 10: A History of Steady Innovation in Pediatrics
102 0 2 6 / / 20 Years of Foundation Building Cannulated Screws 2008 PediNail System 2012 RESPONSE Scoliosis 2016 Orthex® External Fixation 2020 MD Orthopedics® Bracing 2025 LAUNCHLAUNCH LAUNCH ACQUIRE Hip Systems LAUNCH ACQUIRE 95+ Systems Broadest Portfolio across: Trauma & Def Scoliosis Sports Me
Slide 11: Provide a Broad Product Portfolio
112 0 2 6 / / 02 Provide a Broad Product Portfolio Strong Foundation of Implants
Slide 12: Strong Innovation & R&D
122 0 2 6 / / Strong Innovation & R&D 02 Provide a Broad Product Portfolio Multi-year super cycle • Entered a multi-year product super cycle, with multiple launches expected over several years Building Platforms • Focus on platform & product family development rather than isolated products Surgeon-l
Slide 13: Innovation RoadMap
132 0 2 6 / / Innovation RoadMap02 Provide Broad Product Portfolio Iota Motion 3P Hip Platform PNP | Tibia GIRO Playbook Surgical Response Rib & Pelvic DF2® VERTEGLIDE Limited Entering a “Super-Cycle” of Differentiated Product Launches LaunchedLaunchedLaunched PediHip® Rigid Hippo Brace
Slide 14: Innovation RoadMap: Super-Cycle of Product Launches
142 0 2 6 / / Innovation RoadMap02 Provide Broad Product Portfolio Entering a “Super-Cycle” of Differentiated Product Launches eLLi Pin to Bar Ex- Fix Predictive Planning PNP | Retro Knee ‘Tractor FIX PNP | SD 3P | Knee VerAxis Scoliosis Limited 1H27 2H27Limited Traxio Halo Gravity 3P Small | Mini
Slide 15: Accelerating Sales Growth Post-IPO
152 0 2 6 / / Accelerating Sales Growth Post-IPO Through Strategic Investment and Innovation $37.3 $45.6 $57.6 $72.6 $71.1 $98.0 $122.3 $148.7 $204.7 $236.3 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Total Revenue ($M) 2016 2025 CAGR U.S. Independent Sales Consultants 90 232 11% Instrument Se
Slide 16: Increasing ROI on Set Deployments
162 0 2 6 / / Increasing ROI 12 18 18 14 20 22 21 17 10 0% 5% 10% 15% 20% 25% 30% $0 $50 $100 $150 $200 $250 $300 2018 2019 2020 2021 2022 2023 2024 2025 2026 Set Deployment Efficiencies Reducing set deployments as a percentage of revenue while continuing to take share Revenue (Left) Set Deployment
Slide 17: Strategic Acquisitions & Partnerships
172 0 2 6 / / Strategic Acquisitions & Partnerships 202020192017 2022 04 Expand Market with M&A 2021 2023 2024 2026 Partnership Acquisition
Slide 18: OPSB Key Growth-Strategic Objectives
182 0 2 6 / / OPSB Key Growth-Strategic Objectives Aggressive market-based clinic expansion strategy Accelerate R&D with increasing number of YoY launches Scale OPSB selling channel and sales force – grow with current portfolio of products Launch 4 products in 2024 and 5 in 2025 18 new markets by 20
Slide 19: OPSB Market Expansion
192 0 2 6 / / OPSB Market Expansion Pace of Market Expansion +4 markets in 2025 +6 markets in 2026 +8 markets in 2027 OPSB clinics expected to be in 27 territories in 2027 out of 80 target territories
Slide 20: OPSB ROI and Timing for Clinic Expansion
202 0 2 6 / / OPSB ROI and Timing for Clinic Expansion 1-4 Clinics per market expected Greenfield Acqui-Hire Initial Investment $200k-$500k $500K-$1M EBITDA Goal Positive EBITDA by end of first full year Positive EBITDA by end of first full year FCF Goal After first full year Within first year ROI G
Slide 21: OPSB Opportunity – $2.2B
212 0 2 6 / / Motion Assist Devices Fracture Fixation Devices Specialty Casting Spine Halo Traction, Other Specialty Solutions 300 U.S. Pediatric Centers U.S. Potential Target Market 1 — $1.0B OPSB Opportunity – $2.2B 2 0 2 6 / / 1 Management’s Estimate as of January 2026 Levity Device for Gait Assi
Slide 22: Physician Education and Awareness
222 0 2 6 / / Physician Education and Awareness OP Hands-on sales training and support • Annually invests 3% of sales on clinical education • Conducts >700 product/training sessions per year Continuous education • Major Sponsor of the prominent pediatric orthopedic societies Market development • Fos
Slide 23: Differentiated Pediatric Systems Driving Growth
232 0 2 6 / / Trauma & Deformity +19% CAGR 14 68 2016 2025 $26.8 $166.3 2016 2025 Pediatric Systems Revenue +22% CAGR Scoliosis >4X Growth 3 17 2016 2025 $9.3 $66.0 2016 2025 Pediatric Systems Revenue >6X Growth 2025 Revenue by Product Family Trauma & Deformity Scoliosis Sports Medicine70% of Revenu
Slide 24: Strong History of Y/Y Growth
242 0 2 6 / / $0.6 $3.0 $7.1 $10.2 $16.1 $19.6 $23.7 $31.0 $37.3 $45.6 $57.6 $72.6 $71.1 $98.0 $122.3 $148.7 $204.7 $236.3 $271.5 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Strong History of Y/Y Growth ($M) 400% 137% 44% 58% 22% 21% 31% 20% 22% 26%
Slide 25: Revenue Seasonality
252 0 2 6 / / Seasonality Drives Stronger Performance in Summer Months and Holiday Periods 22% 27% 26% 25% 19% 27% 29% 25% 21% 27% 27% 25% 22% 26% 27% 26% 22% 26% 26% 26% 22% 26% 27% 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q Re ve nu e as % o f T ot al Y ea r 2021 2022 202
Slide 26: Income Statement Summary
262 0 2 6 / / FY2023 FY2024 FY2025 Revenue $148.7 $204.7 $236.3 Growth % 22% 38% 15% Gross profit $111.3 $148.6 $172.7 Margin % 75% 73% 73% Operating expenses $138.0 $183.6 $211.9 Operating loss ($26.8) ($35.0) ($39.2) Net (loss) income ($21.0) ($37.8) ($39.6) EPS diluted ($0.92) ($1.64) ($1.69) Inc
Slide 27: Adjusted EBITDA Reconciliation
272 0 2 6 / / Adjusted EBITDA Reconciliation Three Months Ended September 30, 2025 2026 Net loss ($11.8) ($5.9) Interest expense, net 1.8 2.6 Other expense (income), net 0.6 - Income tax charge (benefit) (0.1) (0.1) Depreciation and amortization 5.3 5.6 Intangible asset impairment 2.3 0.6 Stock-base
Slide 28: Adjusted EPS Reconciliation
282 0 2 6 / / Adjusted EPS Reconciliation Three Months Ended September 30, 2025 2026 Loss per share, diluted (GAAP) ($0.50) ($0.25) Intangible asset impairment 0.10 0.03 Fair value adj. of contingent consideration - (0.03) Tariffs 0.01 0.01 Restructuring charges 0.10 - Acquisition-related costs 0.04
Slide 29: Free Cash Flow
292 0 2 6 / / Free Cash Flow ($M) $9 $15 $(21) $(17) $(30) $(13) ($50) ($40) ($30) ($20) ($10) $0 $10 $20 $30 2024 2025 Cash Used For Working Capital/Other Sets Deployed Adj. EBITDA ($42) ($15) Total Year Quarterly YTD $6 $7 $(4) $(2) $(5) $(3) ($30) ($25) ($20) ($15) ($10) ($5) $0 $5 $10 $15 3Q25 3
Slide 30: Balance Sheet
302 0 2 6 / / Balance Sheet Assets Cash, cash equivalents & short-term investments $44.9 Accounts receivable 59.5 Inventory (net) 141.9 Other current assets 6.9 Total Current Assets 253.2 PP&E (net) 47.0 Intangibles and goodwill 208.9 Total Assets $509.1 Liabilities Accounts payable $24.5 Debt 98.4
Slide 31: 2026 Guidance
312 0 2 6 / / 2026 Guidance FY2026 Revenue $270.0 to $273.0 Adjusted EBITDA ~$25.0 Free Cash Flow Breakeven FY2026 2026 Total Revenue Growth % 14% to 16% Set Deployment ~$10.0 Assumptions Full Year 2026 Guidance ($ in Millions)
Slide 32: Investment Summary
322 0 2 6 / / Investment Summary Only diversified company focused exclusively on pediatric orthopedics Large, underpenetrated market opportunity in pediatrics Highly concentrated customer base with targeted commercial strategy Broad product portfolio with innovative solutions Only provider committed
Slide 33: 2850 Frontier Drive Warsaw, IN 46582 ph: 574.268.6379 or 77.268.6339 fax: 574.268.6302 www.OrthoPediatrics.com2
2850 Frontier Drive Warsaw, IN 46582 ph: 574.268.6379 or 877.268.6339 fax: 574.268.6302 www.OrthoPediatrics.com2 0 2 6 / /
OrthoPediatrics — Investor Presentation (October 2026) on 6ix